Actavis divests China subsidiary
DUBLIN — Actavis last week announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co. to acquire Actavis’ interest in Actavis (Foshan) Pharmaceuticals Co., an Actavis subsidiary based in Foshan, China.
Actavis intends to continue further commercial operations in China in collaboration with its preferred business partners.
"Actavis is focused on strengthening our investment in high-growth markets where our size and scale allow us to maintain a competitive presence with the leading companies in the market," Sigurdur Oli Olafsson, president, Actavis Pharma, said. "Our operations in Foshan were limited in scope and we believe that their value will be better capitalized on by Chiral, which will add manufacturing and marketing capabilities allowing them to expand their portfolio and strengthen their position in the Chinese market."
Purdue Pharma names president and CEO
STAMFORD, Conn. — Purdue Pharma on Monday named Mark Timney as president and CEO.
"We found a proven leader in Mark Timney," said Raymond Sackler, co-founder and board member of Purdue. "I am confident that his capabilities and experience, coupled with Purdue’s culture of excellence, will grow our business and strengthen our healthcare industry leadership."
Timney brings more than 20 years of pharmaceutical sales and marketing experience to Purdue, including success in designing and executing strategies to achieve market leadership. Prior to joining Purdue, he was president of Merck US, where he managed sales and marketing, managed markets and payers.
With Timney’s guidance, Purdue will continue advancing research and development initiatives and pioneering new commercial models.
Before coming to the United States, Timney served for seven years as Merck’s country manager in Korea and then Japan. Prior to that, he held leadership positions for more than four years at Merck Australia. Before joining Merck, he spent eight years in sales and marketing at a number of multinational pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia and Roussel Labs in the United Kingdom.
Timney succeeds John Stewart, who has retired from Purdue.
Walgreens Infusion Services selected as preferred provider for Makena
DEERFIELD, Ill. — Walgreens Infusion Services on Monday announced that it has been selected as the preferred provider of home administration services for Makena (hydroxyprogesterone caproate injection), the only FDA-approved medication to help reduce the risk of preterm birth for clinically indicated patients. Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
The new initiative, Makena @Home, creates access to weekly administration of the only FDA-approved medication for this indication in the home setting when covered by the patient’s insurance, providing an important option for patients and their healthcare providers. The program provides home administration of Makena by trained nurses, along with patient assessment and personalized care plan development, reimbursement/coverage coordination for home administration of therapy and scheduling and administrative support for patients.
“Makena is an important treatment for women at risk for recurrent preterm birth,” said Paul Mastrapa, president of Walgreens Infusion Services. “Makena @Home allows our expert multidisciplinary teams to care for patients in a comfortable and convenient location for them. We’re proud to add Makena @Home to the services we provide to patients in their homes and at alternate treatment sites nationwide each day.”
“Selecting Walgreens Infusion Services for Makena @Home gives us confidence that patients who need their weekly injections of FDA-approved Makena administered at home are receiving high-quality care,” said Greg Divis, CEO of K-V Pharmaceutical Company. “We’re excited to collaborate with a well-respected and widely recognized partner in Walgreens to provide this important option for the patients and providers we work with every day.”
Makena is administered by a healthcare provider as a single dose into the hip area (upper outer area of the buttocks) once a week, rotating sides each week. The goal of a healthy pregnancy is to deliver at term — at least 37 weeks of pregnancy. Makena is the only FDA-approved treatment that may help patients who have delivered preterm in the past stay pregnant longer.